Fundraising by Chinese firms in limbo amid tougher scrutiny of IPOs
-
Chinese companies are staring at the prospects of a drought of new equity
capital as tougher domestic IPO rules and challenges in listing overseas
severely...
1 hour ago
Whoa ... B2 but only 37% subsidized overall ... probably certain specialized drugs non-standard & not subsidisable...
ReplyDelete